Improving medication adherence for patients with metastatic breast cancer
Optimizing an Intervention to Increase Oral Medication Adherence for Metastatic Breast Cancer Patients
European Institute of Oncology · NCT06726889
This study is testing a new way to help people with metastatic breast cancer remember to take their oral medications by using personalized reminders and feedback.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 104 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT06726889 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance adherence to oral anticancer medications among patients with metastatic breast cancer by optimizing an intervention that combines informative documentation, personalized reminders, and feedback. Utilizing a full factorial design, the study will evaluate the effectiveness of these components in promoting medication adherence. The focus is on patients who prefer oral medication due to its convenience, addressing the common issue of non-adherence in this population. By tailoring the intervention to the specific needs of metastatic breast cancer patients, the study seeks to improve treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with metastatic breast cancer who are prescribed oral anticancer agents and have access to a smartphone with internet.
Not a fit: Patients with psychiatric disorders or other comorbidities that may impair their ability to comply with study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve medication adherence, leading to better treatment outcomes for patients with metastatic breast cancer.
How similar studies have performed: While there have been various interventions aimed at improving adherence in early-stage breast cancer patients, this approach specifically targeting metastatic breast cancer patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of metastatic BC * Patients with a prescription for any OAA (i.e. oral chemotherapy, endocrine therapy, and Cyclin-Dependent Kinase 4/6 Inhibitors) * Age \>18 years old * Patients with a personal smart phone with internet access * Willingness and ability to comply with scheduled visits and other trial procedures * Understanding and speaking Italian language * Written informed consent Exclusion Criteria: * Psychiatric disorders or conditions that might impair the ability to give informed consent * Comorbidity that may impact on compliance to study procedures
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (RECRUITING)
Study contacts
- Principal investigator: Gabriella Pravettoni, MD — European Istitute of Oncology
- Study coordinator: Gabriella Pravettoni, MD
- Email: gabriella.pravettoni@ieo.it
- Phone: +39 0257489731
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer, Metastatic Breast Cancer, Oral Anticancer Agents, Oral Medication Adherence